Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.49 |
| ▸ | GGT1 | P19440 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 4/20 | 0.46 |
| ▸ | MMP9 | P14780 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6010258 | 1.00 | MME (0.49) | MMEGGT1NPSR1NAALAD2CYP1A2 | |
| SCHEMBL6010134 | 0.88 | FOLH1 (0.49) | MMENAALAD2L3MBTL1FOLH1 | |
| SCHEMBL6010145 | 0.88 | FOLH1 (0.49) | MMENAALAD2L3MBTL1FOLH1 | |
| SCHEMBL9924201 | 0.86 | MME (0.51) | MMEGGT1NPSR1NAALAD2CYP1A2 | |
| SCHEMBL23925862 | 0.84 | MME (0.56) | MMENPSR1NAALAD2CYP1A2MMP2 | |
| SCHEMBL1921155 | 0.84 | MME (0.56) | MMENPSR1NAALAD2CYP1A2MMP2 | |
| SCHEMBL1921156 | 0.84 | MME (0.56) | MMENPSR1NAALAD2CYP1A2MMP2 | |
| SCHEMBL3574641 | 0.82 | TP53 (0.51) | MMEGGT1NPSR1CYP1A2L3MBTL1 | |
| SCHEMBL28871349 | 0.82 | TP53 (0.51) | MMEGGT1NPSR1CYP1A2L3MBTL1 | |
| SCHEMBL8855103 | 0.80 | ACE (0.54) | MMEGGT1MMP2MMP9L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | SEIWA KASEI COMPANY, LIMITED (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1584320-A1 | COSMETIC PREPARATION CONTAINING GLYCERYLAMINO ACID DERIVATIVE | Seiwa Kasei Company, Limited (JP) | 2005-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | GLA, GPKOW, CUTA | MME 2180/4885GGT1 285/4885NPSR1 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.